文献速递物质与行为成瘾

1990-2019年南美洲苯丙胺、大麻、可卡因和阿片类药物使用障碍的疾病负担:全球疾病负担研究2019系统分析

Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019.
PubMed 文献 · Lancet Psychiatry · 2023-01-01

本研究基于全球疾病负担研究2019,分析了1990至2019年南美洲12国由苯丙胺、大麻、可卡因和阿片类药物使用障碍导致的疾病负担。结果显示,阿片类药物使用障碍负担最高,可卡因使用障碍负担先稳定后下降,男性负担普遍高于女性。研究建议改进苯丙胺、大麻和阿片类药物使用障碍的管理方案,并加强监测。

要点

  • 阿片类药物使用障碍的DALY率在多数南美洲国家最高,巴西和秘鲁的DALY率上升至2019年的82和70/10万。
  • 可卡因使用障碍负担在巴西最高(2019年45 DALY/10万),但整体趋势先稳定后下降,可能反映治疗规划成功。
  • 男性物质使用障碍负担高于女性,主要因可卡因和大麻使用障碍;苯丙胺使用障碍性别差异极小,阿片类无差异。

核心结论

  • 南美洲物质使用障碍负担因物质和国别而异,阿片类药物使用障碍负担最高,可卡因使用障碍负担可能因标准化治疗规划而下降。
  • 需改进苯丙胺、大麻和阿片类药物使用障碍的管理方案,并加强定期调查监测以支持政策制定。

研究设计与样本

  • 基于全球疾病负担研究2019,采用标准化工具(死因集成模型、时空高斯过程回归、疾病建模meta回归)估计12个南美洲国家1990-2019年物质使用障碍的发病率、患病率、死亡率、YLL、YLD和DALY。
  • 分析按性别、国家和年份进行比较,并与区域和全球估计对比。

主要发现

  • 2019年南美洲苯丙胺使用障碍每10万DALY率最高在秘鲁(66 DALY);大麻使用障碍DALY率在智利和哥伦比亚最高(19和18 DALY)。
  • 阿片类药物使用障碍DALY率在巴西和秘鲁上升,2019年最高(82和70 DALY);可卡因使用障碍DALY率巴西最高(45 DALY),接近1990年的两倍。
  • 除巴拉圭外,各物质使用障碍DALY率男性均高于女性;总体负担男性高于女性主要因可卡因和大麻使用障碍。
  • 苯丙胺使用障碍YLD率稳定,秘鲁、巴拉圭和乌拉圭最高(>40 YLD/10万);可卡因使用障碍YLD率在阿根廷、乌拉圭、智利和巴西1990-2010上升,2010-2019下降。

临床怎么用

  • 南美洲国家应改进苯丙胺、大麻和阿片类药物使用障碍的管理方案,并加强物质使用障碍的定期调查监测以提供更准确的政策依据。
  • 可卡因使用障碍负担下降可能反映国家标准化治疗规划的成功,可借鉴相关经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: South America's substance use profile, poverty, income inequality, and cocaine-supplier role make it a unique place for substance use research. This study investigated the burden of disease attributable to amphetamine use disorder, cannabis use disorder (CAD), cocaine use disorder, and opioid use disorder (OUD) in South America from 1990 to 2019, on the basis of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. METHODS: GBD 2019 estimated the incidence, prevalence, mortality, years of life lost (YLL), years of life lived with disability (YLD), and disability-adjusted life-years (DALYs) due to substance use disorders in each of the 12 South American countries (Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela). Data were modelled using standardised tools (ie, the Cause of Death Ensemble model, spatio-temporal Gaussian process regression, and disease modelling meta-regression) to generate estimates of each quantity of interest by sex, location, and year. The analysis included comparisons by sex and country, and against regional and global estimates. FINDINGS: In 2019, the highest amphetamine use disorder burden per 100 000 population in South America was in Peru (66 DALYs). CAD DALY rates per 100 000 in South America were stable between 1990 and 2019, except in Chile and Colombia, which had the highest rates in 2019 (19 DALYs for Chile and 18 DALYs for Colombia). OUD DALYs per 100 000 increased during the period in Brazil and Peru, which in 2019 had the highest rates in South America (82 DALYs for Brazil and 70 DALYs for Peru). In 2019, Brazil had the highest cocaine use disorder DALYs per 100 000 (45 DALYs), nearly double its rate in 1990. DALY rates were higher in males than females for each substance use disorder, except in Paraguay. The overall burden of substance use disorders was higher in males than in females, mainly because of cocaine use disorder and CAD, whereas for amphetamine use disorder, the difference between sexes was minimal, and for OUD there was no difference. For males and females, the highest rate of substance use disorders DALYs per 100 000 was for OUD except in Argentina (in males, 58 DALYs for cocaine use disorder vs 52 DALYs for OUD) and in Paraguay (in females, 77 for amphetamine use disorder vs 50 for OUD). CAD DALY rates were generally the lowest among the substance use disorders for males and females. Amphetamine use disorder YLD rates were reasonably stable throughout the period and were highest in Peru, Paraguay, and Uruguay (>40 YLD per 100 000). For CAD, YLD rates were stable in all countries except Chile and Colombia. Cocaine use disorder YLD rates per 100 000 for the top four countries (Argentina, Uruguay, Chile, and Brazil) increased from 1990 to 2010 (eg, from 19 to 33 in Brazil), but decreased between 2010 and 2019 (eg, from 36 to 31 in Chile). For OUD, YLD rates showed a slight increase in most countries apart from Brazil, which increased from 52 in 1990 to 80 in 2019 and was top among the countries. Amphetamine use disorder YLL rates per 100 000 were highest in Suriname and Peru during the period, although in Suriname it increased from 2·7 in 2010 to 3·2 in 2019, whereas in Peru it decreased from 2·1 to 1·7. The highest YLL rate for cocaine use disorder was in Brazil, which increased from 3·7 in 1990 to 18·1 in 2019. Between 2000 and 2019, Chile and Uruguay showed the highest OUD YLL rates (11·6 for Chile and 10·9 for Uruguay). A high incidence of CAD was found in Chile, Colombia, Guyana, and Suriname. There were high incidences of amphetamine use disorder in Paraguay, cocaine use disorder in Argentina, and OUD in Ecuador. A decrease in annual prevalence for substance use disorders during the period was observed in Venezuela (amphetamine use disorder, CAD, and OUD), Brazil (CAD and amphetamine use disorder), Colombia (amphetamine use disorder and cocaine use disorder), Peru (amphetamine use disorder and cocaine use disorder), Chile and Suriname (amphetamine use disorder), Uruguay (CAD), and Bolivia (OUD). Overall, the cocaine use disorder burden stabilised then decreased. OUD was less prevalent than other substance use disorders but its burden was the highest. INTERPRETATION: The decrease in the burden of cocaine use disorder probably reflects the success of national standardised treatment programmes. Programmes for amphetamine use disorder, CAD, and OUD management should be improved. We did not find an increase in CAD burden in Uruguay, the country with the highest degree of cannabis decriminalisation in the region. Countries in South America should improve monitoring of substance use disorders, including regular surveys to provide more accurate data on which to base policy decisions. FUNDING: The Bill & Melinda Gates Foundation.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Castaldelli-Maia JM, Wang YP, Brunoni AR, et al. Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019. Lancet Psychiatry. 2023. PMID: 36697127. doi:10.1016/S2215-0366(22)00339-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。